Heart Failure - Bayer
Heart Failure - Bayer supports medical education providers in educating primary care clinicians and specialists about HFmrEF and HFpEF to address gaps in knowledge of care standards and therapeutic evidence.
Funder: Bayer
Due Dates: Rolling (monthly review) | At least 45 days before the event (complete application)
Funding Amounts: Purpose-designated educational grants
Summary: Supports medical education on HFmrEF and HFpEF, including disease burden, standards of care, treatment gaps, and therapeutic evidence.
Key Information: Individuals and group practices are outside scope, and providers must supply their latest accreditation letter and status.
Description
Bayer US supports medical education on heart failure with mildly reduced or preserved ejection fraction (HFmrEF and HFpEF), focusing on left ventricular ejection fraction of at least 40%. The program addresses educational needs among primary care clinicians, including nurses and physician assistants, and specialists in cardiology, endocrinology, nephrology, and internal medicine. Priorities include contemporary disease definitions, epidemiology, clinical outcomes, pathophysiology, coexisting conditions, standards of care, treatment gaps, real-world use of recommended therapies, and residual risk.
A further focus is the unique properties of non-steroidal mineralocorticoid receptor antagonists compared with steroidal agents, efficacy evidence from FINEARTS-HF and relevant subanalyses and FINEHEART, and safety and tolerability. Preferred formats are enduring activities, downloadable slides, podcasts, live virtual programs, and social media outreach.
